Table 3.
Clinical Relevance discussion | Strategy for specific reporting | No. (%) |
---|---|---|
Clinical relevance discussed | 24 (57) | |
Clinical relevance not discussed | 18 (43) | |
not reached | 16 (39) | |
Full omission for the primary outcome | 7 (44) a | |
Full omission for all primary outcomes used in the sample size calculationb | 4 (25) a | |
Clinical relevance discussed only as within-group improvements | 4 (25) a | |
Clinical relevance discussed at follow-ups not declared in the sample size calculation | 1(6) a | |
reached | 2 (5) a |
a The Total refers to 16 trials that not discussed the clinical relevance
bComposite outcomes